TrialCompass TCL
Find TrialsAI AssistantLetter GeneratorAbout
Back to results
RecruitingPriority 4 · Lower priorityNCT06588868

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is studying a new treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

At a glance

Phase
Status
Recruiting
Design
Non-randomized, blind
Enrollment target
400 patients
Primary endpoint
To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.
Ages
18 Years to —
Start date
2025-02-27
Est. completion
2026-07

Locations

0 US sites · 18 total

No US sites currently listed.

Contact

Sponsor
Fondazione Italiana Linfomi - ETS (OTHER)
Contact
Uffici Studi FIL | startup@filinf.it | +390131033153

Tags

CTCLany
TrialCompass — Clinical Trial Summary

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying a new treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 400 patients

Primary endpoint: To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.; To evaluate the different systemic treatment approaches in real life settings in patients with CTCL.

Ages: 18 Years to —

Start date: 2025-02-27 | Est. completion: 2026-07

Locations

0 US sites · 18 total

Contact

Uffici Studi FIL | startup@filinf.it | +390131033153

Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06588868

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.
TrialCompass

A free tool to help patients, caregivers, and clinicians find and understand clinical trials for T-cell lymphoma.

Explore

  • Find Trials
  • AI Assistant
  • Letter Generator
  • About
  • Share Your Feedback
  • Terms of Use
  • Privacy Policy

Data sourced from ClinicalTrials.gov.

For informational purposes only. Not medical advice — always consult your healthcare team.

Built with care for the rare cancer community.

Data last updated: June 2026

Edit with